Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Adelfinger, Marion ^a   Gentschev, Ivaylo ^a,b   De Guibert, Julio Grimm ^a   Weibel, Stephanie ^a   Langbein Laugwitz, Johanna ^a   Härtl, Barbara ^a,c   Escobar, Hugo Murua ^d,e   Nolte, Ingo ^d   Chen, Nanhai G ^b,f   Aguilar, Richard J ^b   Yu, Yong A ^b,f   Zhang, Qian ^b,f   Frentzen, Alexa ^b   Szalay, Aladar A ^a,b,e,f,g  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GENELUX CORPORATION   (United States)

^c Genelux GmbH   (Germany)

^d UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VASCULOTROPIN A;

ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; CAT; CELL LINE; CELL SURVIVAL; CHLOROCEBUS AETHIOPS; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; MAMMARY NEOPLASMS, ANIMAL; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHARMACOKINETICS; TUMOR CELL LINE; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; CATS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; FEMALE; GENE EXPRESSION; GENETIC VECTORS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SINGLE-CHAIN ANTIBODIES; TRANSDUCTION, GENETIC; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905641030     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104337     Document Type: Article

References (37)

1. Hayes HM Jr, Milne KL, Mandell CP (1981) Epidemiological features of feline mammary carcinoma. Vet Rec 108: 476-479.
2. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR (1968) Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 40: 307-318.
3. Bostock DE (1986) Canine and feline mammary neoplasms. Br Vet J 142: 506-515.
4. Patnaik AK, Liu SK, Hurvitz AI, McClelland AJ (1975) Nonhematopoietic neoplasms in cats. J Natl Cancer Inst 54: 855-860.
5. Hayden DW, Nielsen SW (1971) Feline mammary tumours. J Small Anim Pract 12: 687-698.
6. Weijer K, Hart AA (1983) Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst 70: 709-716. (Pubitemid 13079152)
7. Chen NG, Szalay AA, Buller RM, Lauer UM (2012) Oncolytic viruses. Adv Virol 2012: 320206.
8. Jourdier TM, Moste C, Bonnet MC, Delisle F, Tafani JP, et al. (2003) Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 10: 2126-2132. (Pubitemid 37536762)
9. Gentschev I, Patil SS, Adelfinger M, Weibel S, Geissinger U, et al. (2013) Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered 4: 84-89.
10. Buckel L, Advani SJ, Frentzen A, Zhang Q, Yu YA, et al. (2013) Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. Int J Cancer.
11. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, et al. (2009) Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A 106: 12915-12920.
12. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676. (Pubitemid 36749215)
13. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974. (Pubitemid 43093963)
14. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
15. Kamstock D, Elmslie R, Thamm D, Dow S (2007) Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 56: 1299-1309. (Pubitemid 46763942)
16. Millanta F, Lazzeri G, Vannozzi I, Viacava P, Poli A (2002) Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas. Vet Pathol 39: 690-696.
17. Islam MS, Matsumoto M, Hidaka R, Miyoshi N, Yasuda N (2012) Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis. Vet J 192: 338-344.
18. Patil SS, Gentschev I, Adelfinger M, Donat U, Hess M, et al. (2012) Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody. PLoS One 7: e47472.
19. Weibel S, Hofmann E, Basse-Luesebrink TC, Donat U, Seubert C, et al. (2013) Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer. J Transl Med 11: 106.
20. Nelson-Rees WA, Weaver J, Riggs JL (1972) Chromosomes of two strains of a feline cell line (F 1 B) permanently shedding a C-type virus. Proc Soc Exp Biol Med 139: 6-9.
21. Sterenczak KA, Willenbrock S, Barann M, Klemke M, Soller JT, et al. (2009) Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms. Gene 434: 35-42.
22. Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, et al. (2010) Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68. J Oncol 2010: 736907.
23. Martin I, Garcia T, Fajardo V, Rojas M, Hernandez PE, et al. (2007) Technical note: Detection of cat, dog, and rat or mouse tissues in food and animal feed using species-specific polymerase chain reaction. J Anim Sci 85: 2734-2739. (Pubitemid 47606289)
24. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA (2008) Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol 10: 1235-1248. (Pubitemid 351663917)
25. Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, et al. (2012) Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 7: e37239.
26. de Queiroz GF, Dagli ML, Fukumasu H, Zavala AA, Matera JM (2010) Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs. J Vet Diagn Invest 22: 105-108.
27. Zizzo N, Patruno R, Zito FA, Di Summa A, Tinelli A, et al. (2010) Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model. Leuk Lymphoma 51: 291-296.
28. Patruno R, Arpaia N, Gadaleta CD, Passantino L, Zizzo N, et al. (2009) VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med 13: 555-561.
29. Garber K (2006) China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 98: 298-300.
30. MacNeill AL, Moldenhauer T, Doty R, Mann T (2012) Myxoma virus induces apoptosis in cultured feline carcinoma cells. Res Vet Sci 93: 1036-1038.
31. Gentschev I, Patil SS, Petrov I, Cappello J, Adelfinger M, et al. (2014) Oncolytic virotherapy of canine and feline cancer. Viruses 6: 2122-2137.
32. Braghiroli MI, Sabbaga J, Hoff PM (2012) Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 12: 567-580.
33. Angarita FA, Acuna SA, Ottolino-Perry K, Zerhouni S, McCart JA (2013) Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses. Trends Mol Med 19: 378-392.
34. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, et al. (2007) Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15: 1686-1693. (Pubitemid 47289013)
35. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, et al. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16: 183-194.
36. Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, et al. (2010) Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol 2010: 489759.
37. John LB, Howland LJ, Flynn JK, West AC, Devaud C, et al. (2012) Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 72: 1651-1660.